<DOC>
	<DOCNO>NCT02087176</DOCNO>
	<brief_summary>A Lead-in Phase II Multicentre , Randomised , Double-Blind Study Comparing AZD1775 plus antimitotic agent Placebo plus antimitotic agent Previously Treated Non-Small-Cell Lung Cancer Patients</brief_summary>
	<brief_title>A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel Treat Lung Cancer</brief_title>
	<detailed_description>This multicentre trial consist open-labelled single cohort lead-in ( Part A ) follow phase II double-blind , randomise , placebo-controlled comparison AZD1775 ( placebo ) antimitotic agent . Review central laboratory fresh tumour archival tumour sample require prior study entry ass TP53 mutation status . However , subject allow enter single cohort ( Part A ) regardless TP53 mutation status ( wild-type mutant ) . In addition , patient single cohort Part A treatment group ask consent limited sample collection assessment pharmacokinetic parameter .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antimitotic Agents</mesh_term>
	<criteria>Inclusion Criteria Provision inform consent prior study specific procedure Histologic cytologic diagnosis advance NSCLC , exclude large cell neuroendocrine , mixed NSCLC/smallcell histology Failure one prior platinumbased doublet treatment advance NSCLC ( either due progressive disease toxicity ) Measurable disease measure Response Evaluation Criteria Solid Tumours ( RECIST ) criteria version 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 Mandatory availability tumour tissue ( archival fresh archival available ) TP53 test Male female ≥18 yearsofage Subjects may receive radiation palliation prior start study treatment recover side effect therapy Absolute neutrophil count ( ANC ) ≥1500/μL Haemoglobin ( Hgb ) ≥9 g/dL Platelets ≥100,000/uL Adequate liver function define : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) within normal limit ( WNL ) ≤2.5 x upper limit normal ( ULN ) , liver metastasis present Serum bilirubin WNL Adequate renal function Ability swallow oral medication Fertile male subject willing use least one medically acceptable form birth control duration study 2 week treatment stop Female subject childbearing potential fertile female subject childbearing potential agree use adequate contraceptive measure Predicted life expectancy ≥12 week Willingness ability comply study followup procedure Ability understand investigational nature study give write informed consent Most recent chemotherapy ≤21 day recover side effect &gt; Grade 1 . Use study drug ≤21 day 5 halflives ( whichever short ) prior first dose AZD1775 Wide field radiotherapy ( include therapeutic radioisotope strontium 89 ) administer ≤28 day limit field radiation palliation ≤7 day prior start AZD1775 recover side effect therapy Major surgical procedure ≤28 day begin AZD1775 , minor surgical procedure ≤7 day Known central nervous system ( CNS ) disease Any known hypersensitivity contraindication component study treatment ( AZD1775 docetaxel ) Any follow cardiac disease currently within last 6 month define New York Heart Association [ NYHA ] ≥ Class 2 Pregnant lactate Concurrent administration medication food strong inhibitor Serious active infection time treatment , another serious underlie medical condition would impair ability subject receive protocol treatment Presence active cancer , history treatment invasive cancer ≤3 year Psychological , familial , sociological , geographical condition permit compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>NSCLC</keyword>
</DOC>